重组抗人CD56单抗(N901)流式 | Syd Labs PA007347.m1
重组抗人CD56单克隆抗体(克隆号 N901) ，小鼠IgG1 Kappa(Syd Labs货号：PA007347.m1)是用哺乳动物细胞生产的重组抗体，适用于流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）等研究，纯度>95%。其不变区为小鼠Mouse IgG1 Kappa (mIgG1或m1)，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007347.m1 |
|---|---|
| 产品名称 | 重组抗人CD56单抗(N901)流式 | Syd Labs PA007347.m1 |
| 英文名 | Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901), Mouse IgG1 Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 神经细胞粘附分子，NCAM，CD56，MSK39，神经细胞黏附分子1，NCAM1 |
| 概述 | Syd Labs提供重组小鼠IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | N901 |
| 同种型 | 小鼠 IgG1 kappa |
| 特异性 | 该重组 N901 抗体与人 CD56 蛋白特异性结合 |
| 免疫源 | 重组抗人CD56单克隆抗体（克隆：N901）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，含0.09%叠氮化钠 |
| 偶联 | 非偶联 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 重组抗人CD56单克隆抗体(克隆号 N901) ，小鼠IgG1 Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 12个月，保存在2 至 8°C。 请勿冻结。 |
| 注意事项 | PA007347.m1 Syd Labs提供重组小鼠IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）。 |
文献
PA007347.m1: Syd Labs重组抗人CD56单克隆抗体(克隆号 N901)，小鼠IgG1 Kappa（Recombinant Anti-human CD56 Monoclonal Antibody (Clone: N901), Mouse IgG1 Kappa）
重组N901抗体可结合人CD56蛋白。CD56是一种表达于神经元、神经胶质细胞和骨骼肌表面的同源结合糖蛋白，是神经谱系分化的标记物。在造血系统中，CD56表达于自然杀伤（NK）细胞以及包括γδ T细胞和活化的CD8+ T细胞在内的其他淋巴细胞，同时也表达于树突状细胞。CD56在细胞-细胞粘附、神经突生长、突触可塑性以及学习与记忆过程中发挥重要作用。
抗人CD56单抗(N901)部分参考文献:
1. Reduced Immunosenescence of Peripheral Blood T Cells in Parkinson’s Disease with CMV Infection Background
Kustova, S. A., et al. Biomedicines. 2021 Dec 2;9(12):1819. PMID: 34944635
“Immunosenescence is a process of remodeling the immune system under the influence of chronic inflammation during aging. Parkinson’s disease (PD) is a common age-associated neurodegenerative disorder and is frequently accompanied by neuroinflammation. Thus, PD is characterized by reduced peripheral blood T cell immunosenescence, even against the background of CMV infection.”
2. Surface NKG2C Identifies Differentiated γδT-Cell Clones Expanded in Peripheral Blood
Kovalenko, E. I., et al. Front Immunol. 2021 Feb 16;11:613882. PMID: 33664730
“T cells that express CD56 in peripheral blood of healthy humans represent a heterogeneous and poorly studied subset. In both CD56+ and CD56- subsets most of the NKG2C+ T cells had a phenotype of highly differentiated CD8+ TEMRA cells. Thus, NKG2C expression in highly differentiated CD56+ T cells was associated with the most expanded γδ T cell clones.”
3. Alterations in the CD56- and CD56+ T Cell Subsets during COVID-19
Kustova, S. A., et al. Int J Mol Sci. 2023 May 16;24(10):9047. PMID: 37240393
“This work aimed to analyze the activation and differentiation of both circulating NKT-like cells and CD56- T cells during COVID-19 among intensive care unit (ICU) patients, moderate severity (MS) patients, and convalescents. Severe COVID-19 was accompanied by a decrease in the proportion of CD8+ T cells, mainly due to the CD56- cell death, and a redistribution of the NKT-like cell subset composition with a predominance of more differentiated cytotoxic CD8+ T cells. Overall, our findings suggest an antiviral role of CD56+ T cells in COVID-19.”
4. HLA-DR Expression in Natural Killer Cells Marks Distinct Functional States, Depending on Cell Differentiation Stage
Kust, S. A., et al. Int J Mol Sci. 2024 Apr 23;25(9):4609. PMID: 38731828
“HLA-DR-positive NK cells, found in both healthy individuals and patients with different inflammatory diseases, are characterized as activated cells. In this study, we evaluated the functional features of HLA-DR-expressing NK cells at various stages of differentiation. We demonstrated that HLA-DR expression marks distinct functional states of NK cells depending on their differentiation stage.”
5. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Ghiringhelli, F., et al. Nat Med. 2023 Aug;29(8):2080-2089. PMID: 37563240
“Although patients with microsatellite instable metastatic colorectal cancer benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. The single-arm, phase 1b/2 MEDITREME trial evaluated the safety and efficacy of durvalumab plus tremelimumab combined with mFOLFOX6 chemotherapy in first line. The combination of durvalumab–tremelimumab with mFOLFOX6 was tolerable with promising clinical activity in MSS mCRC.”